Scientific Papers

Evaluation of clinical efficacy, adverse reactions, and safety of PD-1 inhibitors combined with chemotherapy when treating advanced gastric cancer | BMC Gastroenterology


  • Freddie Bray BSc., Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA: ACancer Journal for Clinicians,2018,68(6).

  • Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015[J]. CA Cancer J Clin. 2016;66(2):115–32.

    Article 
    PubMed 

    Google Scholar
     

  • National Health Commission of the people’s Republic of China. Norms for diagnosis and treatment of GC (2018 Edition) [J]. Electron J Compr Oncol Therapy 2019,5(01):55–82.

  • Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagoGC[J]. N Engl J Med. 2008;358(1):36–46.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Zheng Rongshou S, Kexin et al. Analysis of the prevalence of malignant tumors in China in 2015 [J]. Chin J Oncol,2019(01):19–28.

  • Kazuki Sumiyama. Past and current trends in endoscopic diagnosis for early stage GC in Japan[J]. GC,2017,20(1).

  • Terme M, Pernot S, Marcheteau E, et al. VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in Colorectal cancer[J]. Cancer Res. 2013;73(2):539–49.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Kohei S. Toshihiko Doi,Mikhail Dvorkin.Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic GC (TAGS): a randomised, double-blind, placebo-controlled, phase3 trial[J]. The Lancet Oncology,2018,19(11).

  • Bang YJ, Van Cutsem E, Feyereislova A. Et a1. Trastu⁃zumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oe⁃sophageal junction cancer(TOGA): a phase 3, open-label, ran⁃domised controlled tria [J]. Lancet. 2010;376–9742–:687–97.

    Article 

    Google Scholar
     

  • Yazici O, Sendur M A, Ozdemir N, et al. Targeted thera⁃pies in GC and future perspectives [J]. World J Gastro⁃enterol. 2016;22(2):471–89.

    Article 
    PubMed 

    Google Scholar
     

  • Li X, Shao C, Shi Y, et al. Lessons learned from the blockade of immune checkpoints in cancer immunotherapy[J]. J Hematol Oncol. 2018;11(1):31.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Comprehensive molecular characterization. Of gastric adenocarcinoma[J]. Nature. 2014;513(7517):202–9.


    Google Scholar
     

  • Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy[J]. Nat Rev Cancer. 2012;12(4):252–64.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Muro K, Chung HC, Shankaran V, et al. Pembrolizumab for patients with PD-L1-positive advanced GC (KEYNOTE-012): a multicentre, open-label, phase 1b trial[J]. Lancet Oncol. 2016;17(6):717–26.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Fuchs CS, Doi T, Jang RW, et al. Safety and Efficacy of Pembrolizumab Monotherapy in patients with previously treated Advanced gastric and gastroesophageal Junction Cancer:phase 2 clinical KEYNOTE-059 Trial[J]. JAMA Oncol. 2018;4(5):e180013.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Cao, Maomao. Chen Wanqing. The prevalence, prevention and control of malignant tumors in China [J]. Clin Oncol China2019, 46(3): 145–9.

  • Liu Min Z, Qian L, Fengyu S, Xuejun. Meta analysis of the efficacy and safety of apatinib combined with tigio when treating advanced GC [J]. Modern oncology medicine,2020,28(17):3009–15.

  • Bao Xiaoyan C. Application progress of PD-1/PD-L1 inhibitors in immunotherapy of advanced non-small cell Lung cancer [J]. Zhejiang Med. 2019;41(2):204.


    Google Scholar
     

  • Shan Yujie L, Ping L, Yalei et al. Meta analysis of the efficacy and safety of ICIs when treating advanced GC or esophagogastric carcinoma [J]. Study on prevention and treatment of tumor,2021,48(02):166–72.

  • Qilin F, Hongli L. Research progress of ICIs in advanced GC [J]. J Practical Oncol 2020,35(06):479–85.

  • Han Lu S, Yan, Dai Guanghai. Research status and prospect of second-line and posterior-line drug therapy for advanced GC [J]. Chinese medical journal,2021,101(05):369–73.

  • Xu Ruihua T, Kaiyuan. Progress of chemotherapy for advanced GC [J]. cancer,2009,28(10):1108–13.

  • Yi B, Liqi Z. Selection of chemotherapy for advanced GC [J]. Clin Oncol China,2016(1):21–6.

  • Tingting S, Xianhe M, Xue Y et al. Treatment of advanced GC [J]. J Jilin Med Coll 2018,39(4):301–3.

  • Wei Suxian. An observational study of two Drugs combined with three Drugs combined with first-line chemotherapy when treating advanced GC [D]. Huazhong University of Science and Technology; 2016.

  • Yamada Y, Higuchi K, nishikawa K, et al. Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 inchemotherapy-nalve patients with advanced GC [J]. Ann Oncol. 2015;26(1):141–8.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Kito Y, Machida N, et al. Phase II study of S-1plus oxaliplatin 130 mg/m2in Japanese patients with advanced GC [J]. Int J Clin Oncol. 2018;23:1084–9.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Nakayama N, Ishido K, Chin K, et al. A phase I study ofS-1 in combination with nab-paclitaxel in patients with unresect⁃able or recurrent GC [J]. GC. 2017;20(2):350–7.

    CAS 

    Google Scholar
     

  • Kohei S. Mustafa Özgüroğlu,Yung-Jue Bang.Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial[J]. The Lancet,2018,392(10142).

  • Taroh Satoh,Yoon-Koo Kang. Exploratory subgroup analysis of patients with prior trastuzumab use in the ATTRACTION-2 trial: a randomized phase III clinical trial investigating the efficacy and safety of nivolumab in patients with advanced gastric/gastroesophageal junction cancer[J]. GC,2020,23(3).

  • Weimin, Wang. Ilona. Effector T cells abrogate stroma-mediated Chemoresistance in Ovarian Cancer[J]. Cell,2016,165(5).

  • Wang Qian S, Jian W, Xiaoyue L, Ziang C, Jie. Lin Jun. Advances in molecular targeted drug therapy and immunotherapy for advanced GC [J/OL]. Journal of Wuhan University (Medical Edition):1–6[2021-03-09].

  • Zitvogel L, galluzzi L, smyth MJ, et al. Mechanism ofaction of conventional and targeted anticancer therapies: reinstat⁃ing immunosurveillance [J]. Immunity. 2013;39(1):74–88.

    Article 
    CAS 
    PubMed 

    Google Scholar
     

  • Vacchelli E, Senovilla L, Eggermont A, et al. Trial watch: chemotherapy with immunogenic cell death inducers [J/OL]. Oncoimmunology. 2013;2(3):e23510.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar
     

  • Bang Y J, Kang Y K, Catenacci D V, et al. Pembrolizumabalone or in combination with chemotherapy as first-line therapy forpatients with advanced gastric or gastroesophageal junction adeno⁃carcinoma: results from the phase II nonrandomized KEYNOTE-059 study [J]. GC. 2019;22(4):828–37.


    Google Scholar
     

  • Zhao Z, Feng L. Logistic regression analysis of risk factors and Improvement of Clinical Treatment of Traumatic Arthritis after total hip arthroplasty (THA) in the treatment of Acetabular fractures. Comput Math Methods Med. 2022;2022:7891007.

    PubMed 
    PubMed Central 

    Google Scholar
     

  • Gao G, Li C, Fan W, Zhang M, Li X, Chen W, Li W, Liang R, Li Z, Zhu X. Brilliant glycans and glycosylation: Seq and ye shall find. Int J Biol Macromol. 2021;189:279–91.

    Article 
    CAS 
    PubMed 

    Google Scholar
     



  • Source link